Alpelisib (BYL719)

Phase 2

Novartis AG (NVS)

00%

What is LOA?

Phase 2

Development Phase

Upcoming Catalysts

Historical Events

Regulatory Approvals

Upcoming Catalysts

What are catalysts?

Mar '27

NVSPhase 2$284.2B

Alpelisib (BYL719) Phase 2 Est. Readout

Alpelisib (BYL719)• Megalencephaly-capillary Malformation Polymicrogyria Syndrome (MCAP)20

Mar 2027~Confirmed

CT.gov

00%

Competitive Landscape

0 competitors in Megalencephaly-capillary Malformation Polymicrogyria Syndrome (MCAP)

View Full Landscape

Drug Information

Target Indication

Megalencephaly-capillary Malformation Polymicrogyria Syndrome (MCAP)

Clinical Trial

NCT05577754

Last updated: 8/19/2026

Patent & Exclusivity

No patent data available. Pre-approval drugs may not have Orange Book listings.

Source: FDA Orange Book

Drug Science

Mechanism of action & safety profile

Developer

NVS

Novartis AG

Pharmaceutical Preparations•Europe•NYSE

Related Pipeline

AIN457 300 mgPhase 3

Chronic Plaque Type Psoriasis

Verteporfin PDTPhase 3

Pathological Myopia

Certican®Phase 3

Renal Interstitial Fibrosis

[68Ga]Ga-PSMA-11Phase 3

Prostatic Neoplasms

VemurafenibPhase 3

Melanoma

View full pipeline

Get Catalyst Alerts

Receive weekly digests of upcoming catalysts